Results 81 to 90 of about 159,660 (245)
Advanced Healthcare Materials, EarlyView.A novel blood‐brain barrier‐penetrating terpolymer nanoparticle to deliver brain‐derived neurotrophic factor (BDNF) for the treatment of Alzheimer's disease (AD) is designed. The BDNF‐TPN significantly enhances BDNF accumulation in the brain following intravenous injection, reduces apoptosis and neuroinflammation, thus promoting neuronal survival and ...
Lily Yi Li +8 more
wiley +1 more source
Advances in Hematology, 2014 Background and Objectives. Interactions between sickle cells involving CD 49d, CD36, and the vascular endothelium may initiate vasoocclusion leading to acute painful episodes and multiple organ failure. Materials and Methods.
Duni Sawadogo +5 more
doaj +1 more source
Advanced Healthcare Materials, EarlyView.Can luminol detect faecal inflammation? This study explores the development and optimisation of a rapid novel assay ‐ Myeloperoxidase Luminol Reaction (MPOLR) for the detection of faecal myeloperoxidase activity. This simple and rapid luminol‐based approach competes with clinically validated faecal biomarkers in predicting endoscopic findings in ...
Viraj Kariyawasam +14 more
wiley +1 more source
Granular Hydrogels as Modular Biomaterials: From Structural Design to Biological Responses
Advanced Healthcare Materials, EarlyView.Granular hydrogels are now emerging as promising biomaterials due to their inherent microporousity, injectability, and modularity. They have shown improvements in cell viability and migration, cellular/tissue infiltration, host tissue integration, mitigated foreign body response, and tissue regeneration.
Asmasadat Vaziri +6 more
wiley +1 more source
Diagnostic Accuracy of Tissue Transglutaminase and Combined Assay of Tissue Transglutaminase and Deamidated Gliadin Peptide in Children with Coeliac Disease: A Cross-sectional Study [PDF]
Journal of Clinical and Diagnostic ResearchIntroduction: Coeliac Disease (CD) is a systemic immune disorder caused by gluten in genetically susceptible individuals. A serological screening assay for CD has been designed to detect Immunoglobulin A (IgA) and IgG anti-tissue Transglutaminase (a-tTG)
Pankaj Kumar Yadav +3 more
doaj +1 more source
Transforming Cancer Diagnosis and Therapy Through Fluorescent Hydrogels: A Review
Advanced Healthcare Materials, EarlyView.This article reviews fluorescent hydrogel systems for cancer detection, monitoring, and therapy. Mimicking the tumor microenvironment, these hydrogels enable real‐time imaging and targeted drug delivery. The review discusses design strategies, labeling techniques, and applications, highlighting challenges and future opportunities in cancer diagnostics ...
Elahe Masaeli +2 more
wiley +1 more source
Frontiers in MicrobiologyChagas disease (CD), caused by the protozoan Trypanosoma cruzi, is an important public health problem, occurring mainly in Latin America. The disease has a major social and economical effect, negatively impacting the life of the infected individuals, and
Carlos Ananias Aparecido Resende +18 more
doaj +1 more source
Unlocking the secrets of celiac disease: the crucial role of HLA genes in diagnosis, symptoms, and prognosis. [PDF]
Batna Journal of Medical SciencesCeliac disease (CD) is a systemic autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals, primarily manifesting as gastrointestinal symptoms. The primary environmental factor is gluten, (the soluble alcohol fraction of
Nada BOUTRID, Hakim RAHMOUNE
doaj +1 more source
Advanced Healthcare Materials, EarlyView.Comparison of therapeutic and diagnostic applications of a surface‐emitting light source with multiwavelength emission characteristics. Abstract Conventional light‐emitting‐diode‐based light sources suffer from rigidity, localized heating, and poor adaptability to skin deformation, limiting their use in skin‐attached medical devices.
In Ho Kim +10 more
wiley +1 more source
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. [PDF]
, 2014 BackgroundFTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis.
Blanc, Caroline A +2 more
core +1 more source